Compare BTBT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | GYRE |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 583.1M | 606.4M |
| IPO Year | 2017 | 2004 |
| Metric | BTBT | GYRE |
|---|---|---|
| Price | $1.29 | $5.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 24.3M | 60.8K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,560,320.00 | $275,000.00 |
| Revenue This Year | $38.96 | $19.88 |
| Revenue Next Year | $89.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $1.25 | $5.44 |
| 52 Week High | $4.55 | $9.42 |
| Indicator | BTBT | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 32.17 | 43.36 |
| Support Level | $1.25 | $5.78 |
| Resistance Level | $2.42 | $8.28 |
| Average True Range (ATR) | 0.11 | 0.27 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 9.80 | 15.18 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.